information

Whoever comes in this website may find a hint

Phage therapy is influenced by:

Phage therapy is influenced by:

Country :
the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: a lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Chronolability
Mutation rate
Phenotypical delay
Phage cocktail
My point of view

From Wikipedia


If the target host* of a phage therapy treatment is not
an animal the term "
biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

"In silico"

From:"Genomics,Proteomics and Clinical Bacteriology", N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.

Tuesday 17 February 2015

Quality and Safety Requirements for Sustainable Phage Therapy Products

Suggested reading

Link

Link


  "This paper enumerates all phage therapy product related quality and safety risks known to the authors, as well as the tests that can be performed to minimize these risks, only to the extent needed to protect the patients and to allow and advance responsible phage therapy and research".




" To avoid the mistakes of the past (which lead to the current antibiotic resistance crisis), phage therapy products should not exclusively be developed and marketed as antibiotics, i.e., applying current pharmacoeconomic principles. Ideally, phage therapy should be coordinated and standardized (in a first instance) by national phage therapy centers, which operate under the supervision of relevant public health authorities and in interaction with private stakeholders".

 

Expert Consensus Quality and Safety Requirements for Sustainable Phage Therapy Products: 

 A. Production environment

 B. Production processes, equipment and materials

 C. Quality Assurance and Quality Control (QA/QC) specifications

       C.1. Host bacteria used in production (stock suspensions)

       C.2. Bacteriophages (Master Seed lots)

       C.3. Bacteriophages (Working Seed lots/Active Substances)       
       C.4. Finished products
 D. Shelf life of phage stock suspensions, working solutions and finished products (at recommended storage conditions)
 E. Surveillance